Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV003851964 | SCV004659115 | uncertain significance | not provided | 2022-12-25 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on SPTBN2 protein function. This variant has not been reported in the literature in individuals affected with SPTBN2-related conditions. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 1774 of the SPTBN2 protein (p.Glu1774Lys). |
| Ambry Genetics | RCV005281507 | SCV005942875 | uncertain significance | Inborn genetic diseases | 2025-02-25 | criteria provided, single submitter | clinical testing | The c.5320G>A (p.E1774K) alteration is located in exon 26 (coding exon 25) of the SPTBN2 gene. This alteration results from a G to A substitution at nucleotide position 5320, causing the glutamic acid (E) at amino acid position 1774 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |